icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
The HBV capsid assembly modulator JNJ-379 is a potent inhibitor of viral replication across full length genotype A-H clinical isolates in vitro
 
 
  Reported by Jules Levin
AASLD 2017 Oct 20-24 Wash DC
 
AASLD:Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-56136379, a Novel HBV Capsid Assembly Modulator, in Non-cirrhotic, Treatment-nave Patients with Chronic Hepatitis B.- (11/01/17)
 
Jan Martin Berke1, Thierry Verbinnen1, Ying Tan2, Pascale Dehertogh1, Karen Vergauwen1, Koen Vandyck1, Oliver Lenz1;
1Janssen Research & Development, Beerse, Belgium;
2Janssen China Research & Development Center, Shanghai, China

1205171

1205172

1205173

1205174

1205175

1205176

1205177

1205178